AMLX vs VKTX
AMLX: Clinical-stage biotech developing novel therapies for endocrine and neurodegenerative disorders, with a lead GLP-1 receptor antagonist for post-bariatric hypoglycemia. VKTX: Viking is developing VK2735, a novel dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and metabolic disorders, targeting a high-growth market currently dominated by single-agent GLP-1 therapies.
Side-by-side fundamentals
| Metric | AMLX | VKTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $17.70 | $37.31 | |
| Market cap as of 2026-07-23 | $2.0B | $4.3B | |
| PEG as of 2026-07-23 | n/a | -0.04 | |
| Net margin as of 2026-07-23 | -94.6% | n/a | |
| Gross margin as of 2026-07-23 | +82.8% | n/a | |
| Operating margin as of 2026-07-23 | -99.2% | n/a | |
| ROE as of 2026-07-23 | -55.7% | -71.3% | AMLX higher |
| ROA as of 2026-07-23 | -50.7% | -65.3% | AMLX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | -0.20 | 0.65 | |
| 1-year return as of 2026-07-22 close | +125.3% | +16.2% | AMLX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.